LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...

Oral 8-aminoguanine (8-AG) treatment preserved retinal structure and rod function in aged Fischer 344 rats, significantly ...

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...

Thanks to advancements in early detection and treatment options, it's possible to live a long and healthy life after being ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

A study by the Journal of the American Medical Association found that weight loss in middle age can decrease all-cause ...

An oral drug that improves vision in DME [diabetic macular edema]  would be a game changer because it would be more ...

Ocugen ( NASDAQ: OCGN) disclosed on Tuesday that its gene therapy candidate, OCU410ST, has been granted rare pediatric ...

Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the designation ...